Nuclease-Resistant Aptamers to Botox and Anthrax Toxins
Nuclease-Resistant Aptamers to Botox and Anthrax Toxins
批准号:
6736672
负责人:
John G Bruno
金额:
$9.99万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-04-15 至 2004-10-14
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by investigator):
Botulinum toxin and anthrax are two likely bioweapons of choice in military attacks or terrorism against the United States. As such, effective post-exposure therapies, such as antitoxins, to both agents are required. Operational Technologies (OpTech) has extensive experience in the area of DNA aptamer development for the detection of biowarfare agents and biotoxins via its Senior Scientist. OpTech proposes to team with Prof. James Chambers of the Biochemistry Department at the University of Texas at San Antonio (UTSA). Together, the OpTech-UTSA team will develop 2'-pyrimidine modified nuclease-resistant "shielded" DNA aptamers by the SELEX process to botulinum toxin (BOTOX) and the three anthrax toxin components (edema factor, lethal factor, and protective antigen). "Shielded aptamers" are well suited to eventual in vivo therapeutic use and would be of low immunogenicity. In Phase I, OpTech will generate shielded aptamers to several serotypes (at least A, B and E) of BOTOX and will determine their relative binding affinities for the intact "derivative" toxin as well as the separate heavy (100 kD) and light 50 kD) chains. In Phase II, OpTech will develop and test anti-anthrax toxin component shielded aptamers as well as clone and sequence all promising aptamers reactive against either toxin family.
Development of "shielded" (nuclease-resistant) aptamers as toxin inhibitors with greater affinity than antibodies or other antidotes, in general, guarantees the owner of the technology entry into a growing biodefense market. If successful in this project, OpTech will use the knowledge gained to develop improved inhibitors of other bacterial toxins, such as cholera toxin, as well as snake and spider venoms. The therapeutic market for such products would be immense, because DNA is nontoxic and hypoallergenic (does not induce a significant immune response), thus avoiding "serum sickness" or anaphylaxis upon secondary use. Such reagents could also be used in environmental biosensors or diagnostic test kits for detection of BOTOX and anthrax toxins in body fluids or environmental samples.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
--
发表时间:
2008-12
期刊:
Journal of biomolecular techniques : JBT
影响因子:
--
作者:
[Maomian Fan;Shelly Roper McBurnett;C. Andrews;A. Allman;J. Bruno;J. Kiel]
通讯作者:
Maomian Fan;Shelly Roper McBurnett;C. Andrews;A. Allman;J. Bruno;J. Kiel
DOI:
10.3390/ph6030340
发表时间:
2013-03-19
期刊:
Pharmaceuticals (Basel, Switzerland)
影响因子:
--
作者:
[Bruno JG]
通讯作者:
Bruno JG
Development of Anti-OLAM Aptamers as Novel Analgesics (Phase 2)
-
批准号:9059113
-
项目类别:
-
资助金额:$46.5万
-
财政年份:2012
-
负责人:John G Bruno
-
依托单位:
Development of Anti-OLAM Aptamers as Novel Analgesics
-
批准号:8306470
-
项目类别:
-
资助金额:$14.72万
-
财政年份:2012
-
负责人:John G Bruno
-
依托单位:
Nuclease-Resistant Aptamers for Anthrax Opsonization
-
批准号:6735824
-
项目类别:
-
资助金额:$9.99万
-
财政年份:2004
-
负责人:John G Bruno
-
依托单位:
海外基金